Overview

Bioequivalence Study of Fexofenadine Hydrochloride Orally Disintegrated Tablets 30 mg Under Fasting Condition

Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
To assess the bioequivalence of Fexofenadine Hydrochloride Orally Disintegrating Tablets 30 mg of Dr. Reddy's Laboratories Limited, India comparing with that of Allegra® (containing fexofenadine hydrochloride) Orally Disintegrating Tablets 30 mg of Sanofi - aventis U.S. LLC, Bridgewater, NJ 08807 in healthy, adult, human subjects under fasting conditions. To monitor adverse events and ensure the safety of subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Dr. Reddy's Laboratories Limited
Treatments:
Fexofenadine
Terfenadine